Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2013 / Aug / BAK Off
Glaucoma Anterior Segment Cornea

BAK Off

Is the future of eyedrops preservative-free?

By Mark Hillen 8/31/2013 1 min read

Share

Main Teaser of an Eye for Article Bak Off

Itching. Irritation. Dry eye. In extreme cases, keratosis and scarring. Adverse events occur in one in 10 patients who are on long-term therapy with eyedrops for conditions like glaucoma or uveitis. For many, these side-effects are caused by preservatives.

Why do eyedrops have preservatives?
In essence, to stop bacteria growing. Patients with chronic eye diseases tend to be elderly and have poor sight and reduced dexterity; they can have difficulties using (and reusing) eyedrops in a way that minimizes the chance of bacterial transfer. And bacterial infection is something to be avoided: conjunctivitis is never pleasant, and in cases where the eye isn’t intact, like in corneal abrasion, infections that penetrate into the eye can be serious. Hence the preservatives.

What is used and how does it work?
Benzalkonium chloride (BAK) is the preservative of choice; mercurials, chlorhexidine and chlorobutanol have also been used. BAK is a surfactant; at the concentrations used in eyedrops, it acts as a bactericide, dissolving bacterial cell membranes. BAK also has cleaning properties, and is used at higher concentrations as a detergent in many soaps, cosmetics, disinfectants and spermicides. 

What are the potential side-effects of BAK?
BAK not only irritates the eye, it can also damage ocular structures (1). Often patients use more than one BAK-containing eyedrop and, as Russell Young of the International Glaucoma Association explains: “The allergic response to BAK is dose-related. Anyone on two or three medications has an increased exposure to BAK, increasing the likelihood of strong irritation or an allergic response” (1). This has been mitigated in recent years by the introduction of combined drops. “It has been very useful,” notes Young, “for example, with Cosopt you've got timolol and dorzolomide in the same bottle, reducing the patient’s exposure to BAK.” 

Can BAK be eliminated altogether?
Yes, preservative-free preparations of some of the most commonly-used glaucoma medications (including timolol, pilocarpine, travoprost, tafluprost, bimatoprost, latanoprost and even Cosopt) are either now available, or will be shortly. To minimize bacterial contamination risk, they come in single-use, disposable packaging. This raises some issues – they are small and awkward to use. Despite the packaging containing more than double the volume required for a single use, there is the possibility that none of it will be successfully applied. “A small number of patients have difficulty using the unit dose preservative-free drops – and compliance aids are not yet available to assist them,” Young says. 

So why is BAK still used?
It comes down, partly, to cost. BAK-containing eyedrops cost less than preservative-free eyedrops. Some of the BAK-associated adverse events, like dry eye, can be controlled with different eyedrops, although this also increases the cost. With healthcare systems around the world under pressure to cut costs, and with 90 percent of patients tolerating BAK, “giving preservative-free eyedrops for all patients is difficult to justify,” states Young. On the other hand, those patients who have poor outcomes increase the cost to the healthcare provider. “Every patient must be considered as an individual and treated appropriately,” is Young’s conclusion.

Is BAK always to blame?
No, patients may be sensitive to other eyedrop components. “If you’ve got a patient on multiple drops and they’re starting to develop allergic reactions, it’s difficult to decide if it is the BAK exposure, or one of the compounds from the three drops they’re taking,” says Young. “The ophthalmologist might try replacing BAK-containing eyedrops with preservative-free eyedrops – if these are available, and if appropriate – or go down the laser surgery or trabeculectomy route to reduce exposure to the irritant. It’s a judgment call for the ophthalmologist.” ? 

References

  1. J. Hong and L. Bielory “Allergy to Ophthalmic  Preservatives”, Curr. Opin. Allergy Clin.  Immunol., 9 (5), 447–453 (2009).

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: